Japanese Pharma to 2008: Innovation and Expansion Will Counter the Western Threat

Introduction

Dominated by domestic companies in the past, the Japanese pharmaceutical market is evolving, as regulatory changes stimulate increased competition from western companies and government cost containment measures restrict market growth. The Japanese pharmaceutical companies must focus on building strong pipelines in order to drive both domestic and overseas growth. 

Scope

Benchmarking of leading players across a range of strategic, portfolio and financial measures, supported by an interactive Excel-based comparator tool 

Profiles 17 Japanese pharma companies, providing analysis of the company’s strategy, portfolio and pipeline and 6 year forecasts for key products 

Evaluation of the strategic options available for Japanese pharmas to drive domestic and overseas expansion 

Assessment of the strategies used by western big pharma to increase penetration of the Japanese market 

Report Highlights

Japanese companies must focus on R&D due to the weaknesses of their mature portfolios. In 2002, 71.3% of the leading Japanese companies revenues came from drugs that are more than 10 years old 

Overseas companies must consider their therapeutic focus and marketing capabilities to choose the best Japanese expansion strategy. Although recent changes have made it possible, and indeed far easier for western companies to launch their own products in Japan, many still choose to either out-license products or to co-promote/co-market them 

Fujisawa is forecast to be the best performing Japanese company to 2008, reaping the rewards of its extensive alliance network, which included 20 new corporate agreements from January 2000 to October 2003. Other companies should look to follow suit if they are to successfully drive future growth 

Reasons to Purchase

Benchmark your performance against the leading Japanese pharmas 

Identify the best product sourcing strategy for your company’s position 

Optimize your Japanese market growth strategy through detailed knowledge of the performance of the Japanese pharmas, and local operating conditions. 

December 2003, 383 pages 

Publisher: Datamonitor Pharmaceutical Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/copy_of_Datamonitor_Biotechnology.html#a165